Covaxin / BBV152
Also known as BBV152, Covaxin, Indian vaccine
Key facts
- Drug.caption2
- A vial of Covaxin
- Drug.image
- COVAXIN Logo.svg
- Drug.image2
- Bharat Biotech Covaxin Bangalore BESTpedia.jpg
- Drug.type
- vaccine
- Drug.target
- SARS-CoV-2
- Drug.vaccine_type
- Inactivated
- Drug.tradename
- Covaxin
- Drug.routes_of_administration
- Intramuscular
- Drug.ATC_prefix
- J07
- Drug.ATC_suffix
- BN03
- Drug.legal_status
- Full list of Covaxin authorizations
- Drug.CAS_number
- 2501889-19-4
- Drug.UNII
Article
18 sectionsContents
- Medical uses
- Effectiveness
- Efficacy
- Manufacturing
- History
- Clinical trials
- Phase I and II trials
- Phase III trials
- US Immunobridging and booster Phase II/III trial
- Phase IV trials
- Trials on minors
- Variants
- Authorisations
- India
- Other nations
- See also
- References
- External links
Covaxin (development name, BBV152) is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.
On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use, as the first Indian-developed COVID-19 vaccine to be approved. By 31 January 2022, Covaxin had been granted emergency use approval in 13 countries.